{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:41:57Z","timestamp":1790912517036,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s41669-024-00483-w","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T18:01:39Z","timestamp":1712858499000},"page":"481-492","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6274-9357","authenticated-orcid":false,"given":"Sydney","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Carrico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dessi","family":"Loukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Giannelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"issue":"3","key":"483_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4065\/84.3.274","volume":"84","author":"P Sampathkumar","year":"2009","unstructured":"Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009;84(3):274\u201380. https:\/\/doi.org\/10.4065\/84.3.274.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"483_CR2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40121-021-00567-8","volume":"11","author":"D Curran","year":"2022","unstructured":"Curran D, Callegaro A, Fahrbach K, Neupane B, Vroling H, van Oorschot D, et al. Meta-regression of herpes zoster incidence worldwide. Infect Dis Ther. 2022;11(1):389\u2013403. https:\/\/doi.org\/10.1007\/s40121-021-00567-8.","journal-title":"Infect Dis Ther"},{"issue":"2","key":"483_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s15010-013-0550-8","volume":"42","author":"SY Chen","year":"2014","unstructured":"Chen SY, Suaya JA, Li Q, Galindo CM, Misurski D, Burstin S, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42(2):325\u201334. https:\/\/doi.org\/10.1007\/s15010-013-0550-8.","journal-title":"Infection"},{"key":"483_CR4","unstructured":"Government of Canada. Herpes zoster (shingles) vaccine: Canadian Immunization Guide. 2018. Available at: https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-8-herpes-zoster-(shingles)-vaccine.html. Accessed 18 Jan 2023."},{"issue":"1","key":"483_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12877-017-0420-9","volume":"17","author":"L Varghese","year":"2017","unstructured":"Varghese L, Standaert B, Olivieri A, Curran D. The temporal impact of aging on the burden of herpes zoster. BMC Geriatr. 2017;17(1):30. https:\/\/doi.org\/10.1186\/s12877-017-0420-9.","journal-title":"BMC Geriatr"},{"issue":"11","key":"483_CR6","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.4065\/82.11.1341","volume":"82","author":"BP Yawn","year":"2007","unstructured":"Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341\u20139. https:\/\/doi.org\/10.4065\/82.11.1341.","journal-title":"Mayo Clin Proc"},{"issue":"2 Suppl","key":"483_CR7","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ophtha.2007.10.009","volume":"115","author":"TJ Liesegang","year":"2008","unstructured":"Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology. 2008;115(2 Suppl):S3\u201312. https:\/\/doi.org\/10.1016\/j.ophtha.2007.10.009.","journal-title":"Ophthalmology"},{"key":"483_CR8","volume-title":"Herpes zoster ophthalmicus","author":"M Minor","year":"2022","unstructured":"Minor M, Payne E. Herpes zoster ophthalmicus. Treasure Island: StatPearls; 2022."},{"issue":"1","key":"483_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1741-7015-8-37","volume":"8","author":"RW Johnson","year":"2010","unstructured":"Johnson RW, Bouhassira D, Kassianos G, Leplege A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8(1):37. https:\/\/doi.org\/10.1186\/1741-7015-8-37.","journal-title":"BMC Med"},{"issue":"16","key":"483_CR10","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1503\/cmaj.091711","volume":"182","author":"M Drolet","year":"2010","unstructured":"Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182(16):1731\u20136. https:\/\/doi.org\/10.1503\/cmaj.091711.","journal-title":"CMAJ"},{"key":"483_CR11","unstructured":"National Advisory Committee on Immunization (NACI). Statement on the recommended use of herpes zoster vaccine. 2010. Available at: https:\/\/www.canada.ca\/en\/public-health\/services\/reports-publications\/canada-communicable-disease-report-ccdr\/monthly-issue\/2010-36\/canada-communicable-disease-report.html. Accessed 30 Jan 2023."},{"issue":"9","key":"483_CR12","doi-asserted-by":"publisher","first-page":"220","DOI":"10.14745\/ccdr.v44i09a06","volume":"44","author":"R Warrington","year":"2018","unstructured":"Warrington R, Ismail S, National Advisory Committee on Immunization (NACI). Summary of the NACI update on herpes zoster vaccines. Can Commun Dis Rep. 2018;44(9):220\u20135. https:\/\/doi.org\/10.14745\/ccdr.v44i09a06.","journal-title":"Can Commun Dis Rep"},{"key":"483_CR13","unstructured":"Drug Shortages Canada. Discontinuation report ZOSTAVAX II. Available at: https:\/\/www.drugshortagescanada.ca\/discontinuance\/159386. Accessed 1 May 2023."},{"issue":"5","key":"483_CR14","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s40258-019-00491-6","volume":"17","author":"A McGirr","year":"2019","unstructured":"McGirr A, Van Oorschot D, Widenmaier R, Stokes M, Ganz ML, Jung H, et al. Public health impact and cost-effectiveness of non-live adjuvanted recombinant zoster vaccine in Canadian adults. Appl Health Econ Health Policy. 2019;17(5):723\u201332. https:\/\/doi.org\/10.1007\/s40258-019-00491-6.","journal-title":"Appl Health Econ Health Policy"},{"issue":"8","key":"483_CR15","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/cid\/ciab629","volume":"74","author":"C Boutry","year":"2022","unstructured":"Boutry C, Hastie A, Diez-Domingo J, Tinoco JC, Yu CJ, Andrews C, et al. The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70. Clin Infect Dis. 2022;74(8):1459\u201367. https:\/\/doi.org\/10.1093\/cid\/ciab629.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"483_CR16","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1603800.","journal-title":"N Engl J Med"},{"issue":"22","key":"483_CR17","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087\u201396. https:\/\/doi.org\/10.1056\/NEJMoa1501184.","journal-title":"N Engl J Med"},{"issue":"10","key":"483_CR18","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1080\/21645515.2017.1345399","volume":"13","author":"D Curran","year":"2017","unstructured":"Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, et al. Assessment of the potential public health impact of herpes zoster vaccination in Germany. Hum Vaccin Immunother. 2017;13(10):2213\u201321. https:\/\/doi.org\/10.1080\/21645515.2017.1345399.","journal-title":"Hum Vaccin Immunother"},{"issue":"33","key":"483_CR19","doi-asserted-by":"publisher","first-page":"5037","DOI":"10.1016\/j.vaccine.2018.07.005","volume":"36","author":"D Curran","year":"2018","unstructured":"Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, et al. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36(33):5037\u201345. https:\/\/doi.org\/10.1016\/j.vaccine.2018.07.005.","journal-title":"Vaccine"},{"issue":"2","key":"483_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s13555-018-0236-3","volume":"8","author":"D Watanabe","year":"2018","unstructured":"Watanabe D, Mizukami A, Holl K, Curran D, Van Oorschot D, Varghese L, et al. The potential public health impact of herpes zoster vaccination of people aged \u2265 50 years in Japan: results of a Markov model analysis. Dermatol Ther (Heidelb). 2018;8(2):269\u201384. https:\/\/doi.org\/10.1007\/s13555-018-0236-3.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"5","key":"483_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025553","volume":"9","author":"DAM van Oorschot","year":"2019","unstructured":"van Oorschot DAM, Hunjan M, Bracke B, Lorenc S, Curran D, Starkie-Camejo H. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme. BMJ Open. 2019;9(5): e025553. https:\/\/doi.org\/10.1136\/bmjopen-2018-025553.","journal-title":"BMJ Open"},{"issue":"2","key":"483_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s13555-019-0291-4","volume":"9","author":"M Shiragami","year":"2019","unstructured":"Shiragami M, Mizukami A, Kaise T, Curran D, Van Oorschot D, Bracke B, et al. Cost-effectiveness of the adjuvant recombinant zoster vaccine in Japanese adults aged 65 years and older. Dermatol Ther (Heidelb). 2019;9(2):281\u201397. https:\/\/doi.org\/10.1007\/s13555-019-0291-4.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"483_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/21645515.2019.1657753","volume":"16","author":"A Volpi","year":"2020","unstructured":"Volpi A, Boccalini S, Dari S, Clarke C, Curran D, Loiacono I, et al. The potential public health impact of herpes zoster vaccination in the 65 years of age cohort in Italy. Hum Vaccin Immunother. 2020;16(2):327\u201334. https:\/\/doi.org\/10.1080\/21645515.2019.1657753.","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"483_CR24","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1080\/21645515.2021.2002085","volume":"17","author":"D Curran","year":"2021","unstructured":"Curran D, Van Oorschot D, Matthews S, Hain J, Salem AE, Schwarz M. Long-term efficacy data for the recombinant zoster vaccine: Impact on public health and cost effectiveness in Germany. Hum Vaccin Immunother. 2021;17(12):5296\u2013303. https:\/\/doi.org\/10.1080\/21645515.2021.2002085.","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"483_CR25","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1080\/21645515.2021.1932216","volume":"17","author":"C Lee","year":"2021","unstructured":"Lee C, Jiang N, Tang H, Ye C, Yuan Y, Curran D. Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing. Hum Vaccin Immunother. 2021;17(10):3735\u201346. https:\/\/doi.org\/10.1080\/21645515.2021.1932216.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"483_CR26","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s13555-022-00744-8","volume":"12","author":"L Teng","year":"2022","unstructured":"Teng L, Mizukami A, Ng C, Giannelos N, Curran D, Sato T, et al. Cost-effectiveness analysis update of the adjuvanted recombinant zoster vaccine in Japanese older adults. Dermatol Ther (Heidelb). 2022;12(6):1447\u201367. https:\/\/doi.org\/10.1007\/s13555-022-00744-8.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"483_CR27","doi-asserted-by":"publisher","unstructured":"Statistics Canada. Population estimates on July 1st, by age and sex. 2022. Available at: https:\/\/doi.org\/10.25318\/1710000501-eng. Accessed 31 Mar 2022.","DOI":"10.25318\/1710000501-eng"},{"key":"483_CR28","doi-asserted-by":"publisher","unstructured":"Statistics Canada. Mortality rates, by age group. 2022. Available at: https:\/\/doi.org\/10.25318\/1310071001-eng. Accessed 31 Mar 2022.","DOI":"10.25318\/1310071001-eng"},{"issue":"1","key":"483_CR29","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1186\/s12879-016-1898-z","volume":"16","author":"F Marra","year":"2016","unstructured":"Marra F, Chong M, Najafzadeh M. Increasing incidence associated with herpes zoster infection in British Columbia, Canada. BMC Infect Dis. 2016;16(1):589. https:\/\/doi.org\/10.1186\/s12879-016-1898-z.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"483_CR30","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jpain.2010.02.020","volume":"11","author":"M Drolet","year":"2010","unstructured":"Drolet M, Brisson M, Schmader K, Levin M, Johnson R, Oxman M, et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain. 2010;11(11):1211\u201321. https:\/\/doi.org\/10.1016\/j.jpain.2010.02.020.","journal-title":"J Pain"},{"issue":"5","key":"483_CR31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/BF03405246","volume":"99","author":"M Brisson","year":"2008","unstructured":"Brisson M. Estimating the number needed to vaccinate to prevent herpes zoster-related disease, health care resource use and mortality. Can J Public Health. 2008;99(5):383\u20136. https:\/\/doi.org\/10.1007\/BF03405246.","journal-title":"Can J Public Health"},{"key":"483_CR32","unstructured":"IQVIA. Estimated Shingrix immunization rate from IQVIA CompuScript NRx (March 2022 DM) and IQVIA GPM by Payer (March 2022 DM), both for the Canadian Shingles market. All Rights Reserved; GSK Internal Sales Data (March 2022 DM) for the Canadian Shingles market, as well as population data published by Statistics Canada. The statements, findings, conclusions, views, and opinions contained and expressed in this report are based only in part on data obtained under license from IQVIA Solutions Canada Inc. (IQVIA), and therefore such statements, findings, conclusions, views, and opinions are not necessarily those of IQVIA or any of its affiliated or subsidiary entities. Durham, NC; IQVIA"},{"issue":"25","key":"483_CR33","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1016\/j.vaccine.2021.04.053","volume":"39","author":"A McGirr","year":"2021","unstructured":"McGirr A, Bourgoin T, Wortzman M, Millson B, McNeil SA. An early look at the second dose completion of the recombinant zoster vaccine in Canadian adults: a retrospective database study. Vaccine. 2021;39(25):3397\u2013403. https:\/\/doi.org\/10.1016\/j.vaccine.2021.04.053.","journal-title":"Vaccine"},{"issue":"1","key":"483_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12879-017-2185-3","volume":"17","author":"KJ Friesen","year":"2017","unstructured":"Friesen KJ, Chateau D, Falk J, Alessi-Severini S, Bugden S. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia. BMC Infect Dis. 2017;17(1):69. https:\/\/doi.org\/10.1186\/s12879-017-2185-3.","journal-title":"BMC Infect Dis"},{"key":"483_CR35","unstructured":"Ontario Ministry of Health and Long-Term Care. Ontario Case Costing Initiative Costing Analysis Tool. Acute Inpatient FY 2017\/2018 statistics by most responsible diagnosis ICD-10 Code. 2021. Available at: https:\/\/hsim.health.gov.on.ca\/hdbportal\/. Accessed 15 Jun 2021."},{"key":"483_CR36","unstructured":"Ontario Ministry of Health. Schedule of benefits. Physician services under the Health Insurance Act. 2022. Available at: https:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/physserv\/sob_master_20221201.pdf. Accessed 1 Feb 2023."},{"key":"483_CR37","unstructured":"Ontario Ministry of Health and Long-Term Care. Formulary search. Available at: https:\/\/www.formulary.health.gov.on.ca\/formulary\/. Accessed 1 Apr 2022."},{"key":"483_CR38","doi-asserted-by":"publisher","unstructured":"Statistics Canada. Consumer Price Index, annual average, not seasonally adjusted. 2022. Available at: https:\/\/doi.org\/10.25318\/1810000501-eng. Accessed 31 Mar 2022.","DOI":"10.25318\/1810000501-eng"},{"key":"483_CR39","doi-asserted-by":"publisher","unstructured":"Statistics Canada. Consumer Price Index, monthly, not seasonally adjusted. 2022. Availabel at: https:\/\/doi.org\/10.25318\/1810000401-eng. Accessed 1 Apr 2022.","DOI":"10.25318\/1810000401-eng"},{"key":"483_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7596-1","volume-title":"Self-reported population health: An international perspective based on EQ-5D","author":"A Szende","year":"2014","unstructured":"Szende A, Janssen B, Cabases J. Self-reported population health: An international perspective based on EQ-5D. Dordrecht: Springer; 2014."},{"issue":"34","key":"483_CR41","doi-asserted-by":"publisher","first-page":"E932","DOI":"10.1503\/cmaj.190274","volume":"191","author":"M Drolet","year":"2019","unstructured":"Drolet M, Zhou Z, Sauvageau C, DeWals P, Gilca V, Amini R, et al. Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study. CMAJ. 2019;191(34):E932\u20139. https:\/\/doi.org\/10.1503\/cmaj.190274.","journal-title":"CMAJ"},{"issue":"7","key":"483_CR42","doi-asserted-by":"publisher","first-page":"489","DOI":"10.7326\/M15-0093","volume":"163","author":"P Le","year":"2015","unstructured":"Le P, Rothberg MB. Cost-effectiveness of herpes zoster vaccine for persons aged 50 years. Ann Intern Med. 2015;163(7):489\u201397. https:\/\/doi.org\/10.7326\/M15-0093.","journal-title":"Ann Intern Med"},{"key":"483_CR43","unstructured":"Canada's Drug and Health Technology Agency (CADTH). Guidelines for the Economic Evaluation of Health Technologies: Canada \u2014 4th Edition. Available at: https:\/\/www.cadth.ca\/guidelines-economic-evaluation-health-technologies-canada-4th-edition. Accessed 18 Jan 2023."},{"issue":"12","key":"483_CR44","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/j.vaccine.2012.01.045","volume":"30","author":"M Drolet","year":"2012","unstructured":"Drolet M, Levin MJ, Schmader KE, Johnson R, Oxman MN, Patrick D, et al. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine. 2012;30(12):2047\u201350. https:\/\/doi.org\/10.1016\/j.vaccine.2012.01.045.","journal-title":"Vaccine"},{"key":"483_CR45","doi-asserted-by":"publisher","unstructured":"Statistics Canada. Labour force characteristics, monthly, seasonally adjusted and trend-cycle, last 5 months. 2022. Available at: https:\/\/doi.org\/10.25318\/1410028701-eng. Accessed 5 Apr 2022.","DOI":"10.25318\/1410028701-eng"},{"key":"483_CR46","doi-asserted-by":"publisher","unstructured":"Statistics Canada. Labour productivity and related measures by business sector industry and by non-commercial activity consistent with the industry accounts. 2022. Available at: https:\/\/doi.org\/10.25318\/3610048001-eng. Accessed 5 Apr 2022.","DOI":"10.25318\/3610048001-eng"},{"key":"483_CR47","doi-asserted-by":"publisher","first-page":"A488","DOI":"10.1016\/j.jval.2016.09.821","volume":"19","author":"EA Griffiths","year":"2016","unstructured":"Griffiths EA, Vadlamundi NK. CADTH\u2019s $50,000 cost-effectiveness threshold: Fact or fiction? [abstract PHP278]. Value Health. 2016;19:A488. https:\/\/doi.org\/10.1016\/j.jval.2016.09.821.","journal-title":"Value Health."},{"key":"483_CR48","unstructured":"National Advisory Committee on Immunization (NACI). Update on the use of herpes zoster vaccine. 2016. Available at: https:\/\/www.canada.ca\/en\/services\/health\/publications\/healthy-living\/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed 30 Jan 2023."},{"issue":"1","key":"483_CR49","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1080\/13696998.2021.2008195","volume":"25","author":"S Udayachalerm","year":"2022","unstructured":"Udayachalerm S, Renouard MG, Anothaisintawee T, Thakkinstian A, Veettil SK, Chaiyakunapruk N. Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence. J Med Econ. 2022;25(1):26\u201337. https:\/\/doi.org\/10.1080\/13696998.2021.2008195.","journal-title":"J Med Econ"},{"key":"483_CR50","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2168952","author":"N Giannelos","year":"2023","unstructured":"Giannelos N, Ng C, Curran D. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: an updated critical review. Hum Vaccin Immunother. 2023. https:\/\/doi.org\/10.1080\/21645515.2023.2168952.","journal-title":"Hum Vaccin Immunother"},{"key":"483_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2022.101923","volume":"29","author":"NR Meredith","year":"2022","unstructured":"Meredith NR, Armstrong EP. Cost-effectiveness of herpes zoster vaccines in the U.S.: a systematic review. Prev Med Rep. 2022;29: 101923. https:\/\/doi.org\/10.1016\/j.pmedr.2022.101923.","journal-title":"Prev Med Rep"},{"key":"483_CR52","unstructured":"George S, Awan A, O\u2019Connor M, Foster A, Raymond K, Gorfinkel I, et al. Qualitative Interviews with Healthcare Providers and Adult Vaccine Recipients on the Attitudes, Barriers, and Facilitators to Completing the Recombinant Zoster Vaccine Regimen in Canada. Canadian Immunization Conference. 2023. Presented 26 Apr 2023."},{"issue":"50","key":"483_CR53","doi-asserted-by":"publisher","first-page":"7182","DOI":"10.1016\/j.vaccine.2022.10.064","volume":"40","author":"T Ricks","year":"2022","unstructured":"Ricks T, Trent MJ, MacIntyre CR. Predictors of herpes zoster vaccination among Australian adults aged 65 and over. Vaccine. 2022;40(50):7182\u20136. https:\/\/doi.org\/10.1016\/j.vaccine.2022.10.064.","journal-title":"Vaccine"},{"issue":"4","key":"483_CR54","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1007\/s11606-022-07721-z","volume":"38","author":"LP Hurley","year":"2023","unstructured":"Hurley LP, O\u2019Leary ST, Dooling K, Anderson TC, Crane LA, Cataldi JR, et al. Survey of physician practices, attitudes, and knowledge regarding recombinant zoster vaccine. J Gen Intern Med. 2023;38(4):986\u201393. https:\/\/doi.org\/10.1007\/s11606-022-07721-z.","journal-title":"J Gen Intern Med"},{"issue":"3","key":"483_CR55","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1080\/21645515.2015.1008885","volume":"11","author":"TU Yang","year":"2015","unstructured":"Yang TU, Cheong HJ, Song JY, Noh JY, Kim WJ. Survey on public awareness, attitudes, and barriers for herpes zoster vaccination in South Korea. Hum Vaccin Immunother. 2015;11(3):719\u201326. https:\/\/doi.org\/10.1080\/21645515.2015.1008885.","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"483_CR56","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/ICL.0000000000000041","volume":"40","author":"ZP Elkin","year":"2014","unstructured":"Elkin ZP, Cohen EJ, Goldberg JD, Li X, Castano E, Gillespie C, et al. Improving adherence to national recommendations for zoster vaccination through simple interventions. Eye Contact Lens. 2014;40(4):225\u201331. https:\/\/doi.org\/10.1097\/ICL.0000000000000041.","journal-title":"Eye Contact Lens"},{"issue":"8","key":"483_CR57","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/JXX.0000000000000039","volume":"30","author":"M O'Donnell","year":"2018","unstructured":"O\u2019Donnell M, Shurpin K, Janotha B. Improving herpes zoster vaccine rates: the impact of a targeted educational program. J Am Assoc Nurse Pract. 2018;30(8):435\u201340. https:\/\/doi.org\/10.1097\/JXX.0000000000000039.","journal-title":"J Am Assoc Nurse Pract"},{"issue":"4","key":"483_CR58","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.amepre.2022.04.018","volume":"63","author":"J Gatwood","year":"2022","unstructured":"Gatwood J, Brookhart A, Kinney O, Hagemann T, Chiu CY, Ramachandran S, et al. Clinical nudge impact on herpes zoster vaccine series completion in pharmacies. Am J Prev Med. 2022;63(4):582\u201391. https:\/\/doi.org\/10.1016\/j.amepre.2022.04.018.","journal-title":"Am J Prev Med"},{"issue":"4","key":"483_CR59","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1097\/j.pain.0000000000002760","volume":"164","author":"JH Kim","year":"2023","unstructured":"Kim JH, Johnson R, Kovac M, Cunningham AL, Amakrane M, Sullivan KM, et al. Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials. Pain. 2023;164(4):741\u20138. https:\/\/doi.org\/10.1097\/j.pain.0000000000002760.","journal-title":"Pain"}],"updated-by":[{"DOI":"10.1007\/s41669-024-00502-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000}}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00483-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-024-00483-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00483-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T15:25:34Z","timestamp":1721229934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-024-00483-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["483"],"URL":"https:\/\/doi.org\/10.1007\/s41669-024-00483-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s41669-024-00502-w","asserted-by":"object"}]},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]},"assertion":[{"value":"4 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s41669-024-00502-w","URL":"https:\/\/doi.org\/10.1007\/s41669-024-00502-w","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GlaxoSmithKline Biologicals SA funded this study (GSK study identifier: VEO-000312) and all costs related to the development of the publications<b>.<\/b>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sydney George is employed by GSK. Dessi Loukov, Cheryl Ng, Jessica Regan and Nikolaos Giannelos are employed by and hold shares in GSK. Justin Carrico and Katherine A. Hicks are employed by RTI Health Solutions and received consulting fees from GSK to perform the work disclosed in this publication. All authors declare no other financial and non-financial relationships and activities.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts Of Interest\/Competing Interests"}},{"value":"SG, JC, KAH, DL, CN and NG were involved in the design of the study. SG, JC, and KAH collected and generated the data. All authors analyzed and\/or interpreted the data and participated in the development of this manuscript. SG led the publication development and study design. All authors gave their final approval and are accountable for all aspects of the work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"CAPT, 17\u201318 October 2022, Toronto, ON, Canada.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Previous Congress Activities"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The model used during the current study is available from the corresponding author on reasonable request.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Not applicable. GSK study identifier: VEO-000312.","order":11,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical Trial Registration"}},{"value":"Shingrix is a trademark owned by or licensed to GSK.","order":12,"name":"Ethics","group":{"name":"EthicsHeading","label":"Trademark Information"}}]}}